Who is sponsoring NCT07007364?

NCT07007364 is sponsored by Jun Jia.

What drugs are being tested in NCT07007364?

Interventions in NCT07007364: Adebrelimab Combined With Albumin Paclitaxel.

What condition does NCT07007364 study?

NCT07007364 studies Early-Stage Oral Squamous Cell Carcinoma.

Is NCT07007364 still recruiting?

NCT07007364 is currently recruiting now. Last updated 27 June 2025.

Last reviewed 2025-06-27 · How we verify

NCT07007364

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Low-Dose Radiotherapy Combined With Adebrelimab and Single-Agent Albumin-Bound Paclitaxel Chemotherapy for Early-Stage Oral Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Trial

Recruiting now Phase 2 Last updated 27 June 2025

What this trial tests

Phase 2 trial testing Adebrelimab Combined With Albumin Paclitaxel in Early-Stage Oral Squamous Cell Carcinoma in 30 participants. Currently enrolling.

Timeline

19 June 2025

Primary endpoint
1 June 2026

1 June 2027

Quick facts

Lead sponsor	Jun Jia
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	19 June 2025
Primary completion	1 June 2026
Estimated completion	1 June 2027
Sites	1 location across China

Drugs / interventions tested

Adebrelimab Combined With Albumin Paclitaxel — full drug profile →

Conditions studied

Early-Stage Oral Squamous Cell Carcinoma — all drugs for Early-Stage Oral Squamous Cell Carcinoma →

Sponsor

Jun Jia — full company profile →

Who can join

Adults 18 to 70, any sex, with Early-Stage Oral Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, single-arm, Phase II clinical trial. The included population consisted of untreated patients with histologically confirmed stage I-II oral squamous cell carcinoma. Eligible patients received neoadjuvant low-dose radiotherapy combined with adibelizumab and monotherapy with albumin paclitaxel for two cycles. Radical surgical resection is planned to be carried out 3 to 4 weeks after neoadjuvant therapy. Patients who obtain PCR after evaluation by the researchers after the operation will be maintained for 6 cycles of immunomonotherapy. The primary endpoints were the rate of pathological response and the rate of exemption from cervical lymph node dissection. The secondary endpoints included progression-free survival, local control rate, distant metastasis-free rate, overall survival, safety and quality of life of patients, as well as the exploration of biomarkers

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07007364 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jun Jia
Last refreshed: 27 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07007364.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing